Searle Company Ltd
PPSX:SEARL76.06
PKR
-1.34
(-1.73%)
ISIN
PK0061701014
Return %
Stock
S&P 500
1Y
-30.30
14.20
3Y
117.91
81.12
5Y
-35.32
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Tahir Ahmed
- Full Time Employees
- 4,127
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Karachi Pakistan
- IPO Date
- Dec 28, 1993
- Website
- searlecompany.com
- Similar Companies
- Business
- The Searle Company Limited is a Pakistan-based pharmaceutical and healthcare company engaged in the research, manufacturing, marketing, distribution, and export of pharmaceutical formulations, consumer healthcare products, nutritional supplements, and medical devices. Founded in 1965 and headquartered in Karachi, Pakistan, the company operates as a key subsidiary of the International Brands (IBL) Group. The Searle Company Limited serves healthcare providers, government healthcare institutions, retail pharmacies, and consumer markets across Pakistan, South Asia, Southeast Asia, the Middle East, and East Africa. The company offers a diversified product portfolio across major therapeutic and wellness categories, comprising cardiovascular medicines for hypertension, dyslipidemia, and heart failure; respiratory formulations, including antihistamines, cough syrups, bronchodilators, and anti-asthmatic agents marketed under brand names such as Hydryllin and Gravinate; central nervous system treatments, including analgesics, sedatives, antidepressants, and anti-anxiety medications; gastrointestinal therapies, such as antacids, proton pump inhibitors, and oral rehydration solutions including Peditral; pain management, anti-inflammatory, and muscle relaxant agents, including Nuberol Forte and Tramal; anti-infectives and antibiotics, spanning cephalosporins, macrolides, fluoroquinolones, and antifungals; endocrinology and diabetes care products; oncology medications and specialized hospital solutions; dermatological treatments; biosimilars and recombinant biotherapeutics, including recombinant human erythropoietin and filgrastim; consumer health formulations, infant nutrition, dietary supplements, and vitamin complexes; and medical devices, diagnostics, and surgical supplies, such as auto-disable syringes, IV cannulas, and surgical sutures. The company operates multiple cGMP-compliant manufacturing facilities across Karachi and Lahore. In recent corporate developments, The Searle Company Limited has advanced significant strategic initiatives aimed at business reorganization, portfolio enhancement, and international expansion. The company initiated a corporate restructuring and demerger plan to segregate and streamline its manufacturing, marketing, and consumer healthcare business divisions to unlock shareholder value and improve operational efficiencies. In addition, the company entered into strategic alliances and technology licensing partnerships with multinational pharmaceutical enterprises to facilitate local manufacturing and commercialization of complex biosimilars, high-margin oncology products, and sterile injectable formulations. Furthermore, Searle expanded its manufacturing capabilities through the commissioning of upgraded sterile liquid and oral solid dosage production lines, while actively scaling product registrations, distribution agreements, and export volumes across key emerging markets in East Africa, Southeast Asia, and the Central Asian region.